Stocktoria

Adagene Inc. ADAG

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-02-09 · LEI

Adagene Inc. financials (annual)

Revenue
$480000 $700913 $10.2M $9.3M $18.1M $103204 $7.7M 2019202020212022202320242025
Net income
-$16.4M -$42.4M -$73.2M -$80.0M -$18.9M -$33.4M -$17.6M 2019202020212022202320242025
Free cash flow
2019202020212022202320242025

Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue$7.7M$103,204$18.1M$9.3M$10.2M$700,913$480,000
R&D expense$22.0M$28.8M$36.6M$81.3M$68.1M$33.5M$16.2M
Operating income-$21.4M-$36.0M-$23.7M-$83.9M-$72.4M-$43.2M-$19.2M
Interest expense$1.1M$693,323$363,762$202,165$138,096
Income tax-$297,860-$17,553$1.7M$459,055$1.7M
Net income-$17.6M-$33.4M-$18.9M-$80.0M-$73.2M-$42.4M-$16.4M
EPS (diluted)$-0.30$-0.59$-0.35$-1.48$-1.46$-2.67$-1.10
Operating cash flow-$15.7M-$29.7M-$28.5M-$48.6M-$43.4M-$28.5M-$18.2M
Cash & equivalents$74.5M$85.2M$109.9M$143.8M$174.4M$75.2M$92.5M
Total assets$78.3M$89.3M$115.7M$152.4M$189.5M$84.3M$105.9M
Total liabilities$26.4M$38.7M$45.2M$69.3M$33.0M$19.2M$8.7M
Shareholders' equity$35.3M$50.5M$70.6M$83.1M$156.6M-$89.4M-$57.0M

Growth · year-over-year · Revenue CAGR 58.7%

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue growth+7332.8%-99.4%+94.9%-8.7%+1351.7%+46.0%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.